Document is current

Article History

Received: 23 October 2024

Accepted: 12 February 2025

First Online: 3 March 2025

Declarations

:

: The authors declare no competing interests.

: In recent years, breast cancer research has focused on identifying new and significant biomarkers that contribute to cancer progression. CYP1B1 has emerged as a potential biomarker for tumor aggressiveness. Elevated CYP1B1 expression in breast tumors may indicate a more aggressive cancer phenotype, particularly in patients who are estrogen receptor-negative, progesterone receptor-negative, or have p53 mutations. Thus, CYP1B1 could be a novel target for therapeutic intervention. Given the correlation between CYP1B1 overexpression and tumor progression, targeting CYP1B1 might be explored as a therapeutic strategy, especially in patients with aggressive breast cancer subtypes.

: The study was approved by the Research Ethics Committee of the Liga Paranaense de Combate ao Câncer, Hospital Erasto Gaertner (approval no. 23709119.3.0000.0098), ensuring the confidentiality of patient identification at all stages of the study. As a retrospective analysis, the patients’ data were previously collected in the hospital. A waiver of the informed consent form was requested for cases of death and patients who had not visited the institution in the last 2 years.

: Not applicable.